Literature DB >> 16796461

Effect of antibody to CD134 on perforin-mediated cytolysis in human peripheral blood mononuclear cells.

Ming Li1, Yuanchao Zhang.   

Abstract

CD134 (OX40) is a new member of the tumor necrosis factor receptor (TNFR) superfamily. The influence of CD134 on perforin-mediated cytolysis remains obscure. In this study, human peripheral blood mononuclear cells (PBMC) were induced with phytohemagglutinin (50 microg/mL), by using anti-CD134 blocking monoclonal antibody (MAb; 1, 5, and 10 microg/mL) for 6, 12, 24, and 48 h. Perforin-mediated cytolysis against human erythrocytes of PBMC was detected. The expression of perforin mRNA and protein was also measured by reverse transcription-polymerase chain reaction and flow cytometry. Our data showed that the perforin-mediated cytolysis of PBMC was downregulated by various concentrations of anti-CD134 blocking MAb for different times and reached a minimum at 24 h at any concentration. Anti-CD134 blocking MAb induced downregulation of perforin-mediated cytolysis of PBMC in a dose-dependent manner in the range of 1-5 microg/mL. Perforin- mediated cytolysis of PBMC reached a plateau when the concentration of anti-CD134 blocking MAb exceeded 5 microg/mL. Anti-CD134 blocking MAb also induced the inhibition of the expression of perforin protein and mRNA in PBMC. In conclusion, anti-CD134 blocking MAb inhibits perforin-mediated cytolysis of PBMC by, at least in some part, decreasing the production of preforin, which may be useful in treating several autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796461     DOI: 10.1089/hyb.2006.25.145

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  1 in total

1.  Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis.

Authors:  Yan-bin Zhou; Ren-gao Ye; You-ji Li; Can-mao Xie
Journal:  Rheumatol Int       Date:  2008-09-20       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.